Advanced Imaging Techniques for Glioblastoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests three advanced MRI techniques to determine if they can help doctors understand brain tumors, specifically glioblastoma. These methods aim to provide a clearer picture of the tumor environment without requiring surgery or a tissue sample. The goal is to discover why some brain tumors are more difficult to treat. Individuals with glioblastoma scheduled for surgery or a biopsy and who have a noticeable tumor on a recent MRI might be suitable candidates for this study. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants an opportunity to contribute to a breakthrough in brain tumor imaging.
What prior data suggests that these advanced imaging techniques are safe for glioblastoma patients?
Previous studies have shown that CEST MRI, DR-CSI, and Fe-MRI are safe. Research indicates that CEST MRI can produce detailed images of brain tumors without major side effects, aiding doctors in observing tumor changes crucial for treatment decisions. Studies suggest that DR-CSI is well tolerated with minimal side effects, offering insights into the tumor's surroundings without surgery. Fe-MRI uses a contrast agent called ferumoxytol, which is generally safe and provides clear images. These advanced imaging techniques offer a safe, non-invasive way to study brain tumors and could benefit patients with glioblastoma.12345
Why are researchers excited about this trial?
Researchers are excited about these advanced imaging techniques for glioblastoma because they offer a deeper look into the tumor's biology and environment, which current imaging methods might miss. CEST MRI and DR-CSI can provide detailed molecular information about the tumor, potentially allowing for better treatment planning. Fe-MRI, enhanced by ferumoxytol, adds another layer by highlighting blood vessel abnormalities and tumor inflammation. Together, these techniques could lead to more personalized and effective treatment strategies for patients with this aggressive brain cancer.
What evidence suggests that these advanced imaging techniques are effective for assessing the tumor immune microenvironment in glioblastoma?
This trial will evaluate advanced imaging techniques for glioblastoma, including CEST MRI, DR-CSI, and Fe-MRI. Studies have shown that CEST MRI can predict early changes in glioblastoma patients and identify tumor responses to treatment within two weeks. Research indicates that DR-CSI provides detailed information on tissue changes, distinguishing between different types of gliomas without surgery. Ferumoxytol-enhanced MRI has made brain tumors easier to see and is well-tolerated by patients. Together, these imaging techniques offer promising non-invasive methods to understand tumor behavior and glioblastoma's resistance to treatment.678910
Who Is on the Research Team?
Jingwen Yao
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Research Imaging
Participants undergo research CEST MRI and DR-CSI over 30 minutes at research visit 1, followed by ferumoxytol IV administration and Fe-MRI at research visit 2
Standard of Care Procedures
Participants undergo standard of care surgery/biopsy and clinical MRI, along with blood sample collection
Follow-up
Participants are monitored until death
What Are the Treatments Tested in This Trial?
Interventions
- CEST MRI
- DR-CSI
- Fe-MRI
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients undergo research CEST MRI and DR-CSI over 30 minutes at research visit 1, up to 28 days before standard of care surgery/biopsy. Following research CEST MRI and DR-CSI at research visit 1, patients receive ferumoxytol IV over 10-15 minutes. Approximately 24-48 hours later, patients undergo Fe-MRI over 15 minutes at research visit 2. Patients also undergo standard of care clinical MRI and collection of blood samples on study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jonsson Comprehensive Cancer Center
Lead Sponsor
National Center for Advancing Translational Sciences (NCATS)
Collaborator
Citations
Chemical exchange saturation transfer MRI serves as ... - PMC
Recently, CEST MRI already showed the potential to enhance post-treatment response evaluation in glioblastoma [18, 30]. A pre-treatment assessment of tumor ...
Evaluation of Glioblastoma Response to Therapy With ...
Chemical exchange saturation transfer (CEST) provides imaging-based biomarkers of GBM response as early as 2 weeks into the treatment.
Endogenous Chemical Exchange Saturation Transfer MRI for ...
Endogenous CEST MRI offers valuable, potentially unique information in brain tumors, but its diagnostic accuracy remains incompletely known.
4.
analyticalsciencejournals.onlinelibrary.wiley.com
analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/nbm.5282Saturation transfer (CEST and MT) MRI for characterization of ...
Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. Oncotarget. 2018; 9(47): 28772 ...
ISMRM24 - Translational CEST
Improved Differentiation of Glioma Grades through Fluid Exponential Suppression in Chemical Exchange Saturation Transfer (CEST) Imaging · View ...
Amide proton transfer-weighted CEST MRI for radiotherapy ...
Amide proton transfer (APT)-weighted imaging could enable visualization of tumor infiltration, allowing more accurate GTV delineation.
Chemical exchange saturation transfer (CEST) imaging ...
Results. This analysis comprises 33 glioma patients who underwent at least two longitudinal CEST MRIs: before RT (N = 33), then one month (N ...
Molecular Imaging of Brain Tumors and Drug Delivery Using ...
In this review, we will discuss the promises of CEST MRI in the identification of tumors, tumor grading, detecting molecular alterations related to isocitrate ...
CEST MRI For Early Brain Tumor Response To Radiotherapy
Discover the latest research showing how CEST MRI can quantify brain tumor response to radiotherapy earlier, leading to improved patient ...
Reproducibility of APT-weighted CEST-MRI at 3T in ...
In this work, we investigated whether APT-weighted CEST imaging can provide reproducible measurements across scan sessions and scanners.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.